Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial)

Trial Profile

Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Phenprocoumon
  • Indications Atrial fibrillation; Deep vein thrombosis; Pulmonary embolism; Stroke; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms IRIVASC
  • Most Recent Events

    • 12 May 2017 Planned End Date changed from 1 Jan 2018 to 1 Dec 2019.
    • 21 Jul 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2017.
    • 03 Dec 2015 Planned End Date changed from 1 Jan 2016 to 1 Jan 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top